China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)

China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2024-2028)


China TAVR market is expected to reach US$4.04 billion in 2028, growing at a CAGR of 55.55%, for the duration spanning 2024-2028. While, the TMV market in China is forecasted to reach US$4515.5 million in 2028, rising at a CAGR of 146.50%, for the time period of 2024-2028. Factors such as growing prevalence of aortic stenosis, rise in approval of new TAVR products, rise in geriatric population and rapid urbanization would drive the growth of the market. However, the market growth would be challenged by risks associated with TAVR procedures and challenge of patient selection in TMVI. A few notable trends may include rising penetration of TAVR and TMV procedures, decline in prices of transcatheter mitral valve procedures, upcoming major TMVI products and rise in complications in open-heart surgery.

Currently, interventional heart valve therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening.

In particular, driven by China’s favorable policy encouraging innovative medical devices, a growing number of medical device companies have joined the competition of R&D of transcatheter heart valve repair and replacement products in China. Growth in the R&D activities among major players in the country would drive the new products launch and would propel the TAVR and TMV market in China.

Scope of the report:

The report provides a comprehensive analysis of the China TAVR and TMV Market

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The company profiles of leading players (Medtronic PLC, Edwards Lifesciences, Venus MedTech HangZhou Inc., MicroPort CardioFlow Medtech Corporation and Peijia Medical) are also presented in detail.

Key Target Audience:

TAVR and TMV Products Manufacturers

Raw Material Suppliers

End Users (Hospitals, Surgical centers and Medical Institutes)

Research and Development Firms

Medical Technology Companies

Investment Banks

Government Bodies & Regulating Authorities


1. Overview
1.1 Overview of Valvular Heart Diseases
Table 1: Types of Valvular Heart Diseases
1.2 Transcatheter Aortic Valve Replacement (TAVR)
1.3 Comparison Between Types of Valves in TAVR
Table 2: Comparison Between Types of Valves in TAVR
1.4 Transcatheter Mitral Valve Replacement (TMVR)
1.5 Technical Challenges Between TAVR vs. TMVR
Table 3: Technical Challenges Between TAVR vs. TMVR
1.6 Manufacturing Process Of Artificial Valves
Table 4: Manufacturing Process Of Artificial Valves
1.7 Current State and Unmet Needs of Interventional Therapy in China
2. COVID-19 Impact
2.1 Decline in Hospital Visits
Table 5: Number of Hospital Visits in China (2019-2020)
2.2 Fall in Number of Merger & Acquisition (M&A) Deals
Table 6: Number of M&A deals in the Medical Device Sector in China (2019-2020)
3. China Market Analysis
3.1 China Transcatheter Aortic Valve Replacement (TAVR) Market by Value
Table 7: China Transcatheter Aortic Valve Replacement (TAVR) Market by Value (2019-2023)
3.2 China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value
Table 8: China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value (2024-2028)
3.3 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume
Table 9: China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume (2019-2023)
3.4 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast
Table 10: China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast (2024-2028)
3.5 China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast
Table 11: China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast (2023-2028)
3.6 China Transcatheter Mitral Valve (TMV) Market Forecast by Value
Table 12: China Transcatheter Mitral Valve (TMV) Market Forecast by Value (2023-2028)
3.6.1 China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value
Table 13: China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value (2024-2028)
3.6.2 China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value
Table 14: China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value (2024-2028)
3.7 China Transcatheter Mitral Valve (TMV) Treated Patient Volume Forecast
3.7.1 China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast
Table 15: China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast (2024-2028)
3.7.2 China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast
Table 16: China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast (2024-2028)
3.8 China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast
Table 17: China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast (2023-2028)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Prevalence of Aortic Stenosis
Table 18: China Prevalence of Aortic Stenosis (2017-2023)
4.1.2 Rise in Approval of New TAVR Products
Table 19: Major Approved and Marketed TAVR Products in China (2017-2023)
4.1.3 Rise in Geriatric Population
Table 20: China Population – Aged above 65 Years (2017-2023)
4.1.4 Rapid Urbanization
Table 21: China Urban Population (2018-2023)
4.2 Key Trends
4.2.1 Rising Penetration of TAVR and TMV Procedures
Table 22: Penetration Rate of TAVR and TMV Procedures in China (2022-2026)
4.2.2 Decline in Prices of Transcatheter Mitral Valve Procedures
Table 23: Average Prices of TMVI and TMVR in China (2023-2026)
4.2.3 Upcoming Major TMVI Products
Table 24: Upcoming Major TMVI Products
4.2.4 Rise in Complications in Open-heart Surgery
4.3 Challenges
4.3.1 Risks Associated with TAVR Procedures
Table 25: Risks Associated with TAVR Procedures
4.3.2 Challenge of Patient selection in TMVI
5. Company Profiles
5.1 Medtronic PLC
5.1.1 Business Overview
5.2 Edwards Lifesciences
5.2.1 Business Overview
5.3 Venus MedTech HangZhou Inc.
5.3.1 Business Overview
5.4 MicroPort CardioFlow Medtech Corporation
5.4.1 Business Overview
5.5 Peijia Medical
5.5.1 Business Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings